PENCICLOVIR
Clinical safety rating: safe
Animal studies have demonstrated safety
Penciclovir is a nucleoside analog that inhibits viral DNA polymerase. It is phosphorylated by viral thymidine kinase to penciclovir triphosphate, which competitively inhibits viral DNA polymerase and terminates DNA chain elongation.
| Metabolism | Penciclovir is not significantly metabolized; it is primarily excreted unchanged in the urine. |
| Excretion | Renal excretion: >70% as unchanged penciclovir via glomerular filtration and tubular secretion. |
| Half-life | Terminal half-life: 2.0–2.5 hours (healthy adults); prolonged to ~9–10 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjusted based on renal function. |
| Protein binding | <20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 1.5 L/kg (indicating extensive distribution into total body water and tissues). |
| Bioavailability | Topical: Negligible systemic absorption (<1%) after repeated application; oral: not available (only as prodrug famciclovir with ~77% oral bioavailability converted to penciclovir). |
| Onset of Action | Topical (1% cream): Onset of symptom relief (pain, itching) within 1–2 hours of application for herpes labialis; intravenous: not applicable for clinical effect in typical outpatient use. |
| Duration of Action | Topical: Duration of action corresponds to dosing interval (every 2 hours while awake); clinical note: maximal effect if initiated early in prodrome. Systemic: T1/2 determines dosing interval for IV; prolonged effect in renal impairment. |
| Molecular Weight | 253.3 |
Topical: Apply 1% cream every 2 hours while awake (approximately 9 times/day) for 4 days. Oral: 500 mg twice daily for 5 days.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for topical use. For oral: CrCl 30-49 mL/min: 250 mg twice daily; CrCl 10-29 mL/min: 250 mg once daily; CrCl <10 mL/min or hemodialysis: 250 mg after each dialysis. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Topical: Approved for ≥12 years, apply same as adult. Oral: Not approved for <18 years. |
| Geriatric use | No specific adjustment; monitor renal function as clearance may be reduced. |
| 1st trimester | No well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. Animal studies have not shown teratogenicity. |
| 2nd trimester | Same as T1. No known risk based on limited human data and animal studies. |
| 3rd trimester | Same as T1. Minimal systemic absorption suggests low risk. |
Clinical note
No significant drug interactions For topical use only not for ophthalmic or oral use.
| Placental transfer | Not studied in humans; animal studies indicate minimal transfer due to low systemic absorption. |
| Breastfeeding | Not known if penciclovir is excreted in human milk after topical application. Systemic absorption is minimal. Caution should be exercised when administered to a nursing woman. |
■ FDA Black Box Warning
None
| Common Effects | Application site reaction |
| Serious Effects |
Hypersensitivity to penciclovir or any component of the formulation
| Precautions | Use with caution in patients with renal impairment; dose adjustment may be necessary., Apply only to intact skin; avoid contact with eyes or mucous membranes., The safety and efficacy in immunocompromised patients have not been established. |
| Food/Dietary | No clinically significant food interactions for topical penciclovir. Oral or intravenous formulations are not available; therefore, dietary restrictions are not applicable. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Penciclovir is a nucleoside analog antiviral with limited human data. In animal studies (rats, rabbits), no evidence of teratogenicity or fetal harm was observed at systemic exposures up to 80 times the human therapeutic dose. Based on FDA pregnancy category B, no adequate and well-controlled studies in pregnant women exist, but potential benefits may warrant use. Risk cannot be ruled out; use only if clearly needed. |
| Fetal Monitoring | No specific maternal or fetal monitoring required beyond routine prenatal care. For intravenous or oral use (if applicable), monitor for renal function due to excretion, but penciclovir is primarily topical. For severe infections, standard fetal surveillance may be considered. |
| Fertility Effects | No human data on fertility impairment. In animal studies, no adverse effects on fertility or reproductive performance at systemic doses up to 80 mg/kg/day in rats. No known clinical impact on fertility. |
| Clinical Pearls | Penciclovir is a nucleoside analog with activity against HSV-1, HSV-2, and VZV. Topical formulation is indicated for recurrent herpes labialis (cold sores). Application should begin at earliest prodromal symptoms (tingling, itching). Efficacy is modest; systemic antivirals (e.g., valacyclovir, acyclovir) are preferred for severe or frequent episodes. Penciclovir is not for ophthalmic or mucosal use. No significant systemic absorption occurs with topical application. |
| Patient Advice | Apply a sufficient amount to cover all lesions every 2 hours during waking hours for 4 days. · Start treatment at the first sign of a cold sore (tingling, itching, redness) for best results. · Do not apply to eyes, inside the mouth, or on genital areas. · Wash hands before and after applying the cream to avoid spreading infection. · Avoid sharing towels, utensils, or lip products with others while lesions are present. · Sun exposure can trigger recurrences; use lip balm with SPF 30 or higher. · If symptoms worsen or do not improve within 7 days, consult healthcare provider. |